Overview

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

Status:
Not yet recruiting
Trial end date:
2022-09-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of study drug LY3526318 in participants with diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol (H0P-MC-CPMP) which is a protocol to accelerate the development of new treatments for chronic pain.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company